Navigation Links
Survey Finds At-Risk Consumers Interested in OTC Statin

WASHINGTON, Dec. 12 /PRNewswire-USNewswire/ -- According to data released by the National Consumers League today, Americans with unhealthy cholesterol levels would be more likely to consider taking an over-the-counter (OTC) statin option than a prescription (Rx) product, but the likelihood to use an OTC had decreased since 2004. The findings of the survey are being made public on the eve of a joint meeting of two Food and Drug Administration Advisory Committees. At that meeting, members of the public will weigh in on the possibility of making the current Rx cholesterol-lowering statin MEVACOR (lovastatin) available as an OTC drug. The survey was commissioned by NCL and conducted by Harris Interactive(R) between October 25 and November 5, 2007. A total of 710 adult Americans at known moderate risk for high cholesterol participated.

"For the more than 100 million Americans who have high cholesterol, the challenge of keeping the bad number low and the good number high is a very real one," said Sally Greenberg, Executive Director of NCL, the nation's oldest consumer advocacy group. "In this atmosphere of increasing availability of medications without prescriptions, the introduction of an OTC statin could expand the total number of people getting treated for high cholesterol. Are consumers interested in an OTC statin option? According to our survey, they are."

According to the U.S. Department of Health and Human Services, high cholesterol is a major risk factor for heart disease, the leading cause of death in the United States. NCL commissioned the survey to explore whether the ease of an OTC cholesterol-lowering drug would be attractive to those with moderately high cholesterol.

Findings: OTC perceived as more convenient, Rx perceived as more trustworthy

Overall, the majority of those surveyed (82 percent) responded that an OTC statin would be preferable to a prescription statin. For those respondents who say they are more likely to consider taking the OTC product than an Rx product, the OTC is more appealing largely because of convenience factors. OTC statins are viewed as safer, more natural, more suitable for someone who takes charge of his or her health, and less likely to cause side effects than Rx statins. Those who prefer the Rx option have a greater trust in the product and the fact that a doctor prescribed it. The Rx version is generally viewed by at-risk respondents as more effective, more reliable, more trustworthy, and more suitable for someone in poor health than is an OTC statin.

Those most inclined to use the OTC statin include individuals with greater levels of concern about cholesterol, those with higher known cholesterol levels, and those who take vitamins or supplements on a daily basis. The vast majority (98 percent) of those who reported being most concerned about their cholesterol indicated that the OTC product would be appropriate for someone with health care needs much like their own. And 94% of all respondents reported that the OTC product would be appropriate for someone who takes charge of his or her health.

The survey found that people want to know more about OTC statins, and in fact, are more than three times as likely to seek out additional information about the OTC statin than the Rx statin (79 percent vs. 21 percent). They were also much more likely to discuss the OTC product than the Rx product with their doctor (64 percent vs. 36 percent).

Although the survey revealed a strong preference for the OTC option, it found a decline since 2004 in respondents who said they were very or extremely likely to use an OTC statin, from 20% in 2004 to 11% in 2007. While all groups surveyed reported they preferred OTC over Rx, African Americans reported the lowest likelihood of using the OTC product compared with white and Hispanic respondents, and women were less likely than men to report that they are very or extremely likely to use the OTC product.

NCL's Health Associate Ria Eapen will present the survey findings at the Joint Meeting of the Nonprescription Drugs Advisory Committee and the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA tomorrow. For more findings and the complete survey report, visit

About the Survey

NCL commissioned this survey with an unrestricted educational grant from Merck & Co.

This survey was conducted online within the United States by Harris Interactive on behalf of the National Consumers League between October 25 and November 5, 2007 among 710 U.S. residents, aged 35 and older, who are at known moderate risk for developing high cholesterol. African Americans and Hispanics were oversampled so that of the 710 respondents, there were at least 100 African Americans and 100 Hispanics. Results were weighted as needed for age, sex, race/ethnicity, education, region and household income. Propensity score weighting was also used to adjust for respondents' propensity to be online.

All sample surveys and polls, whether or not they use probability sampling, are subject to multiple sources of error which are most often not possible to quantify or estimate, including sampling error, coverage error, error associated with nonresponse, error associated with question wording and response options, and post-survey weighting and adjustments. Therefore, Harris Interactive avoids the words "margin of error" as they are misleading. All that can be calculated are different possible sampling errors with different probabilities for pure, unweighted, random samples with 100% response rates. These are only theoretical because no published polls come close to this ideal.

Respondents for this survey were selected from among those who have agreed to participate in Harris Interactive surveys. The data have been weighted to reflect the composition of the U.S. adult population aged 35 and older. Because the sample is based on those who agreed to be invited to participate in the Harris Interactive online research panel, no estimates of theoretical sampling error can be calculated.

About NCL

The National Consumers League, founded in 1899, is America's pioneer consumer organization. The mission of the National Consumers League is to protect and promote social and economic justice for consumers and workers in the United States and abroad. NCL is a private, nonprofit membership organization. For more information, visit

SOURCE National Consumers League
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Nationwide Survey Reports that Mothers View Cleaning Homes and Toys as Essential to Preventing Colds & Flu
2. Survey Finds U.S. Healthcare Facilities Not Doing Enough to Curb MRSA
3. Replikins LLC Finds West Nile Virus Replikin Count Has Reached Its Highest Recorded Value
4. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
5. Mayo Clinic Study Finds FDA Warning Against Anti-Nausea Drug Droperidol Unnecessary
6. Review of Probiotic Trial Research Finds Only Bifantis(R) Able to Claim Efficacy versus Placebo for IBS Symptoms
7. New Report by Pediatricians Finds Gaps in Preparing to Protect Kids From Pandemic Flu, Offers Recommendations
8. UPDATE: New Report by Pediatricians Finds Gaps in Preparing to Protect Kids From Pandemic Flu, Offers Recommendations
9. Study Finds Starion Instruments Tissue Welding Technology Reduces Pain and Bleeding in Tonsillectomy Patients
10. Providence Hospital Study Finds Communication System Leads to Faster Heart Attack Treatment
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
(Date:11/27/2015)... 27, 2015  Lannett Company, Inc. (NYSE: ... the acquisition of Kremers Urban Pharmaceuticals Inc. (KU), ... biopharmaceuticals company UCB S.A. (Euronext: UCB). ... acquired KU from UCB for total consideration of ... a customary working capital adjustment, a deduction of ...
(Date:11/26/2015)... november 2015 AAIPharma Services Corp./Cambridge ... investering aan van ten minste $15,8 miljoen ... het mondiale hoofdkantoor in Wilmington, ... in extra kantoorruimte en extra capaciteit voor ... behoeften van de farmaceutische en biotechnologische markten. ...
(Date:11/26/2015)... 3D bioprinting market is expected to reach ... by Grand View Research Inc. Rising prevalence of chronic diseases ... is expected to boost the market growth, as 3D bioprinting ... --> 3D bioprinting market is expected to reach ... by Grand View Research Inc. Rising prevalence of chronic diseases ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... ... at the Radiological Society of North America (RSNA) 2015 conference. , Leading ... dictation and speech-enabled documentation software, announced their partnership today at RSNA 2015. ...
(Date:11/30/2015)... ... 30, 2015 , ... World Patent Marketing , a ... household invention that provides an economical and easy way of gaining customized curtains. ... at 2.6%," says Scott Cooper, CEO and Creative Director of World Patent Marketing. ...
(Date:11/29/2015)... St. Petersburg, FL (PRWEB) , ... November 30, ... ... beauty are available today from the new company, Sublime Beauty NATURALS®. All products ... organic and natural products, like essential oils, organic facial serums and USDA Certified ...
(Date:11/29/2015)... ... ... The Cyber Monday deal is a deep 40% or more discount on every item on ... the skin care lover in your circle. Each Christmas, Sublime Beauty offers a special ... serums are staples: Collagen, Retinol and Hyaluronic Serums. , Stocking stuffers like Skin Brushes, natural ...
(Date:11/29/2015)... , ... November 29, 2015 , ... While conventional walkers ... or provide ready access to exercise weights. Fortunately, an inventor from Uniontown, Pa., has ... TOMMY WALKER to enhance the benefits of a standard walker to improve the user’s ...
Breaking Medicine News(10 mins):